Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

Autor: Sara I. Pai, Paolo Bruzzi, Raul Eduardo Giglio, C. René Leemans, Sandrine Faivre, Jean-Pascal Machiels, Lisa Licitra, Viktor Gruenwald, Jan B. Vermorken, Denis Soulières, Tanguy Y. Seiwert

Publikováno v: Pai, S I, Faivre, S, Licitra, L, Machiels, J-P, Vermorken, J B, Bruzzi, P, Gruenwald, V, Giglio, R E, Leemans, C R, Seiwert, T Y & Soulieres, D 2019, ' Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) ', Journal for Immunotherapy of Cancer, vol. 7, no. 1, 96 . https://doi.org/10.1186/s40425-019-0578-0
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-4 (2019)
Journal for ImmunoTherapy of Cancer
Journal for immunotherapy of cancer, Vol. 7, no. 1, p. 96 [1-4] (2019)
Journal for Immunotherapy of Cancer

Two phase III clinical trials (CheckMate 141 and KEYNOTE 040) have independently demonstrated that overall survival (OS) in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients, who have failed platinum-based therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da634989ee9a70f69fe795a2fd292079
https://research.vumc.nl/en/publications/c1c1e633-2e9d-4ce4-a73a-2b87e0e457bd